Easy MediBot Secured U-BOT Patent Rights in Europe
The medical technology firm expanded its intellectual property footprint across 19 European nations.
Updated on Sept. 22, 2026 in Robotics
Live Poll
Is now a good time to invest in companies aggressively pursuing international medical patents?
Easy MediBot has officially registered a patent for its U-BOT uterine suspension robot in 19 European countries, including 18 EU member states and the UK. This milestone follows a registration decision from the European Patent Office received in November 2025.
Why it matters
The company is actively securing international intellectual property rights to prepare for global market entry. This strategic move aims to support the planned commercialization of its robotic surgical technology following domestic product approval.
The U-BOT system integrates voice recognition, remote control, and foot pedal functions to provide surgeons with precise control over the uterus. The device is currently scheduled for commercialization by the first half of 2027.
The players
Easy MediBot
This medical technology company develops robotic surgical systems and control software.
European Patent Office
This intergovernmental organization serves as the regional authority for patent registration across Europe.
WSI
This South Korean firm is the parent organization of Easy MediBot and trades on the KOSDAQ market.
The details
The newly patented technology provides a specialized control system designed for uterine suspension procedures. Easy MediBot has now filed a total of four patent cases overseas, achieving registration for three of those filings.
Timeline
November 2025: Easy MediBot received its registration decision from the European Patent Office.
September 22, 2026: WSI stock price rose 29.94 percent to reach 1,545 Korean won.
Early 2027: The firm will begin preliminary preparations for overseas certifications.
First half of 2027: The company targets the commercial release of the U-BOT system.
The Tech Race
This development follows the standard regulatory requirements established by the European Patent Office's patent granting process. Easy MediBot is now positioning its proprietary surgical robotics against legacy medical devices in an increasingly competitive global automation market.
The patent expansion signifies that hospitals in Europe may soon gain access to advanced uterine suspension robotics. Surgeons will eventually utilize these tools to perform operations with voice-activated and remote-controlled precision.
The takeaway
Securing international patent rights is a vital precursor to gaining regulatory approval for medical robotics. Investors and healthcare providers should monitor the firm's progress toward FDA and CE certification as it approaches the 2027 commercialization target.
Further reading
For more developments in surgical automation, visit our Robotics section.
Source note: This article includes information reported by 조선일보.
Live Poll
Is now a good time to invest in companies aggressively pursuing international medical patents?
